Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

BUY
$8.32 - $15.45 $49,920 - $92,700
6,000 Added 46.88%
18,800 $163,000
Q3 2023

Nov 02, 2023

SELL
$8.25 - $11.35 $825 - $1,135
-100 Reduced 0.78%
12,800 $123,000
Q2 2023

Jul 28, 2023

BUY
$10.1 - $11.6 $13,130 - $15,080
1,300 Added 11.21%
12,900 $137,000
Q1 2023

May 11, 2023

BUY
$10.37 - $12.56 $14,517 - $17,584
1,400 Added 13.73%
11,600 $122,000
Q4 2022

Jan 26, 2023

SELL
$9.9 - $12.43 $41,580 - $52,206
-4,200 Reduced 29.17%
10,200 $0
Q3 2022

Nov 10, 2022

SELL
$10.14 - $12.38 $61,854 - $75,518
-6,100 Reduced 29.76%
14,400 $149,000
Q2 2022

Aug 09, 2022

BUY
$11.05 - $12.72 $29,835 - $34,344
2,700 Added 15.17%
20,500 $236,000
Q1 2022

May 13, 2022

SELL
$10.61 - $12.88 $45,623 - $55,384
-4,300 Reduced 19.46%
17,800 $224,000
Q4 2021

Jan 26, 2022

BUY
$10.86 - $13.95 $39,096 - $50,220
3,600 Added 19.46%
22,100 $258,000
Q3 2021

Nov 15, 2021

SELL
$11.92 - $13.92 $20,264 - $23,664
-1,700 Reduced 8.42%
18,500 $242,000
Q2 2021

Aug 12, 2021

BUY
$10.16 - $13.11 $6,096 - $7,866
600 Added 3.06%
20,200 $260,000
Q1 2021

May 17, 2021

SELL
$9.04 - $11.86 $90,399 - $118,600
-10,000 Reduced 33.78%
19,600 $219,000
Q4 2020

Feb 16, 2021

BUY
$9.05 - $12.2 $29,865 - $40,260
3,300 Added 12.55%
29,600 $337,000
Q3 2020

Nov 09, 2020

BUY
$8.99 - $10.74 $53,940 - $64,440
6,000 Added 29.56%
26,300 $237,000
Q2 2020

Aug 07, 2020

SELL
$9.14 - $11.97 $82,260 - $107,730
-9,000 Reduced 30.72%
20,300 $209,000
Q1 2020

May 12, 2020

BUY
$8.58 - $14.01 $251,394 - $410,493
29,300 New
29,300 $296,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $682M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Tokio Marine Asset Management CO LTD Portfolio

Follow Tokio Marine Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tokio Marine Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Tokio Marine Asset Management CO LTD with notifications on news.